FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL	
	_

OMB Number: 3235-0287
Estimated average burden
hours per response: 0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5	STATEMENT OF CHANGES IN BENEFICIAL OWN
obligations may continue. See	
Instruction 1(b).	Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
	or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* WRIGHT DAVID P					2. Issuer Name and Ticker or Trading Symbol HEALTHCARE ACQUISITION CORP [PIP]									Relationship of Reporting Person(s) to Issuer (Check all applicable) X Director 10% Owner						
(Last) (First) (Middle) C/O PHARMATHENE, INC. ONE PARK PLACE, SUITE 450					Date o	of Earliest ⁻	Trans	action (Mo	onth/E	Day/Year)	-	X Officer (give title X Other (specify below) Chief Executive Officer / Member of Section 13(d) Group								
(Street) ANNAPOLIS MD 21401 (City) (State) (Zip)						4. If Amendment, Date of Original Filed (Month/Day/Year) 08/08/2007									6. Individual or Joint/Group Filing (Check Applicable Line) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
(- 3)				n-Deriv	vativ	e Se	curities	s Ac	auired.	Dis	posed o	f. or E	enef	ficially	Owned					
Date				2. Trans	nsaction n/Day/Year)		2A. Deemed Execution Date, if any (Month/Day/Year)		3. Transa Code (3. Transaction Code (Instr.		4. Securities Acquired (A) of Disposed Of (D) (Instr. 3, 4			5. Amount Securities Beneficial Owned For Reported	lly ollowing	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership (Instr. 4)	
								Code	v	Amount	(A (E) or)	Price	Transaction (Instr. 3 au				-		
Common	Stock, \$0.0	001 par value pe	er share	08/03	08/03/2007				J ⁽¹⁾		50,541	(2)	A	(3)	100,	,541		D		
		001 par value pe		08/10	0/200)7			J ⁽¹⁾		1,274	(4)	A	(3)	101,815			D		
Common	Stock, \$0.0	001 par value pe	er share	08/30	0/200)7			J		100,000		A	(5)	201,	815		D		
			Table II -								osed of, convertil				wned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution E if any (Month/Day	l 4 Pate, T	4. Transaction Code (Instr. 8)		5. Number of 6 Derivative E		6. Date E Expiratio	5. Date Exercisa Expiration Date Month/Day/Year		7. Title of Sec Underl Deriva	Title and Amount Securities derlying rivative Security str. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number derivative Securitie Beneficia Owned Following Reported	Ownersh S Form: Direct (D or Indire (I) (Instr.		Beneficial Ownership ct (Instr. 4)	
					Code	v	(A)	(D)	Date Exercisal		Expiration Date	Title	or Nu	mount umber Shares	Transaction((Instr. 4)		ion(s)			
Stock Option (right to buy)	\$3.28	08/03/2007			A		52,044		07/15/20	03	07/15/2013	Comm Stock		52,044	(6)	52,04	52,044			
Stock Option (right to buy)	\$4.22	08/03/2007			A		41,006		01/18/20	05	01/18/2015	Comm Stock		1,006	(6) 41,00		41,006 D			
Stock Option (right to buy)	\$4.22	08/03/2007			A		6,420		01/01/20	06	01/01/2016	Comm Stock		6,420	(6)	6,42	0	D		
Stock Option (right to buy)	\$4.22	08/03/2007			A		4,063		01/04/20	07	01/04/2017	Comm Stock		4,063	(6)	4,06	3	D		
Unsecured Convertible Note	\$10	08/03/2007			A		5,313		08/03/20	07	08/03/2009	Comm Stock		5,313	(7)	5,31	3	D		
Stock Option (right to	\$5.36	08/30/2007			A		750,000		(8)		08/30/2017	Comm Stock		50,000	(5)	750,0	00	D		

Explanation of Responses:

- 1. Pursuant to the Agreement and Plan of Merger, dated as of January 19, 2007, the Issuer, PAI Acquisition Corp., a Delaware Corporation and a direct wholly-owned subsidiary of the Issuer ("Merger Sub"), and PharmAthene, Inc., a privately held Delaware corporation ("Target"), Merger Sub merged with and into Target as a result of which Target became a wholly-owned subsidiary of the Issuer (the "Merger").
- 2. Received in the Merger in exchange for 1,015,520 shares of Target common stock. The merger agreement provides that the former stockholders of Target may receive additional shares of the Issuer common stock if holders of more than 5% of the Issuer common stock exercise their conversion rights which was to be determined within 3 business days following the effective date of the merger (8/8/07) (the "Adjustment Shares"). The Reporting Person's right to receive a pro rata portion of the Adjustment Shares pursuant to this right became fixed and irrevocable on August 3, 2007, the effective date of the merger. The calculation of the Adjustment Shares issuable was finalized on August 9, 2007. See Note 4 below.
- 3. On August 3, 2007, the effective date of the Merger, the closing price of the Issuer's common stock was \$6.16 per share.
- 4. On August 9, 2007, the pro rata portion of the Adjustment Shares to be received by the Reporting Person was determined.
- 5. On August 30, 2007, the date such stock options were granted and restricted stock was issued, the closing price of the Issuer's common stock was \$5.36 per share.
- 6. Received in the Merger in exchange for 2,284,326 stock options of the Target, issuable upon exercise.
- 7. Received in the Merger in exchange for a convertible note of the Target in the principal amount of \$50,000 (plus accrued interest). Immediately convertible into shares of common stock of Issuer at the rate of \$10 per share.
- 8. The option vests over a 5 year period with 25% vesting on the first anniversary of the grant date or 08/30/2008 and the remainder vesting monthly on a pro-rata basis over the succeeding 48 months following the anniversary date.

Remarks:

the issuance of stock options noted in Note 9 above.

/s/ David P. Wright

** Signature of Reporting Person

09/04/2007

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.